When considering what names to put on your watch list, look for stocks with an 80 or higher RS Rating. Metsera just cleared that benchmark with an upgrade from 66 to 84.
Looking For The Best Stocks To Buy And Watch? Start Here
IBD's unique RS Rating measures market leadership by showing how a stock's price action over the last 52 weeks compares to that of other stocks on the major indexes.
Over 100 years of market history reveals that the market's biggest winners often have an RS Rating of over 80 in the early stages of their moves.
While Metsera is not near an ideal entry right now, see if it goes on to form and break out from a proper base.
Metsera posted 0% EPS growth in its most recent report. Sales gains came in at 0%.
The company holds the No. 214 rank among its peers in the Medical-Biomed/Biotech industry group. Exelixis, Catalyst Pharmaceuticals and TG Therapeutics are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
